9.3 Perioperative Opioid Analgesics, Ketorolac & Reversal

9.3 Perioperative Opioid Analgesics, Ketorolac & Reversal

Opioid analgesics represent the standard pharmacotherapy for blunting the neuroendocrine and hemodynamic stress responses to surgical trauma. While providing profound antinociception, opioids exert significant respiratory, cardiovascular, and gastrointestinal effects. For the Certified Anesthesia Technologist (Cer.A.T.T.), mastering opioid receptor pharmacology, comparative pharmacokinetics, context-sensitive half-times, active metabolite clearance, and reversal protocols is critical for managing delivery infusions, recognizing respiratory failure, and troubleshooting acute clinical crises.

---

Opioid Receptor Pharmacology & Cellular Signal Transduction

Opioids exert their biological effects by mimicking endogenous opioid peptides (endorphins, enkephalins, dynorphins) through stereospecific binding to G-protein-coupled receptors (GPCRs) belonging to the inhibitory Gi/Go family.

CELLULAR MECHANISM OF OPIOID RECEPTORS (Gi/Go Protein Coupling):

                        Opioid Agonist Binding
                                  |
                                  v
                 Activation of Inhibitory G-Protein (Gi/Go)
                                  |
        +-------------------------+-------------------------+
        |                                                   |
        v                                                   v
Inhibition of Adenylyl Cyclase           Modulation of Ion Channels:
- Decreased Intracellular cAMP           1. CLOSES Voltage-Gated Ca2+ Channels
- Reduced Protein Kinase A (PKA)            (Inhibits Presynaptic Neurotransmitter
                                             Release: Substance P, Glutamate)
                                         2. OPENS Inward-Rectifying K+ Channels
                                            (Hyperpolarizes Postsynaptic Membrane,
                                             Preventing Action Potential Generation)

Opioid Receptor Subtypes & Physiological Actions

All pure perioperative opioid agonists (morphine, fentanyl, sufentanil, alfentanil, remifentanil, hydromorphone) exert their primary clinical analgesia and respiratory depression through the Mu receptor.

---

Comparative Pharmacology of Perioperative Opioid Agonists

Understanding the physical and pharmacokinetic differences among opioid agonists enables precise drug selection based on the expected surgical duration and patient comorbidities:

Morphine

Morphine is a natural phenanthrene alkaloid. Because of its low lipid solubility (octanol:water partition coefficient ~1.4), it penetrates the hydrophobic blood-brain barrier slowly. Following intravenous injection, peak clinical effect and peak respiratory depression are delayed for 20 to 30 minutes. Providers who redose morphine too quickly risk dose stacking and severe delayed post-anesthesia hypoventilation.

• Histamine Release: Morphine stimulates non-immunologic mast cell degranulation, releasing histamine. This produces peripheral vasodilation, systemic hypotension, reflex tachycardia, facial/torso flushing, bronchospasm, and injection-site pruritus. It should be used with extreme caution in patients with severe reactive airway disease or hemodynamic instability.
• Metabolite Toxicity in Renal Failure: Morphine undergoes hepatic Phase II glucuronidation into two major metabolites:
  1. Morphine-6-Glucuronide (M6G, the smaller fraction): A potent mu-opioid agonist possessing greater analgesic and respiratory depressant potency than parent morphine.
  2. Morphine-3-Glucuronide (M3G, the majority): Devoid of opioid analgesic activity; acts as a neurotoxin that causes hyperalgesia, allodynia, myoclonus, and seizures. Both metabolites rely exclusively on renal glomerular filtration for clearance. In patients with renal failure, M6G accumulates rapidly, producing delayed, refractory coma and fatal respiratory depression, while M3G produces central nervous system excitation. Morphine is generally avoided in severe renal disease.

Fentanyl (Sublimaze)

Fentanyl is a synthetic phenylpiperidine derivative approximately 100 times more potent than morphine. It possesses high lipid solubility, rapidly crossing the blood-brain barrier to achieve peak effect within 3 to 5 minutes.

• Redistribution Kinetics: The short clinical duration of a single bolus (30 to 60 minutes) is driven by rapid redistribution from the brain into skeletal muscle and adipose tissue. However, fentanyl has a high volume of distribution (Vd = 4 L/kg). Repeated boluses or prolonged infusions (>2 to 4 hours) saturate peripheral reservoirs, resulting in a dramatic increase in its context-sensitive half-time and prolonged postoperative sedation.
• Cardiovascular Profile: Fentanyl causes zero histamine release and minimal direct myocardial depression, providing excellent hemodynamic stability. It causes central vagal stimulation, which can produce bradycardia.
• Metabolism: Metabolized by hepatic cytochrome P450 CYP3A4 into inactive norfentanyl; no active metabolites exist, making it safe in renal failure.

Sufentanil (Sufenta)

Sufentanil is a thienyl analog of fentanyl with a potency 500 to 1,000 times that of morphine (5 to 10 times that of fentanyl). It has the highest affinity for the mu-opioid receptor among perioperative opioids.

• Pharmacokinetic Profile: Despite its extreme potency, sufentanil has a shorter context-sensitive half-time than fentanyl for continuous infusions lasting up to 8 hours. This occurs because of its rapid hepatic clearance (12.7 mL/kg/min) and rapid redistribution, making it an exceptional agent for cardiac surgery and long total intravenous anesthetics.

Remifentanil (Ultiva)

Remifentanil is a synthetic piperidine opioid with an identical potency to fentanyl (100–200x morphine) but possesses an entirely unique chemical structure featuring a methyl ester linkage on the piperidine ring.

REMIFENTANIL METABOLIC CASCADE:

                 Remifentanil (Active Methyl Ester Opioid)
                                    |
                                    v
      RAPID HYDROLYSIS BY NON-SPECIFIC BLOOD & TISSUE ESTERASES
             (Ubiquitous throughout RBCs, plasma, and tissues)
           *DOES NOT depend on pseudocholinesterase / liver / kidney*
                                    |
                                    v
       Remifentanil Acid (Inactive Polar Metabolite: 1/4600 Potency)
                                    |
                                    v
                        Excreted by the Kidneys

• Ultra-Short Pharmacokinetics: Remifentanil has an elimination half-life of 3 to 10 minutes and a constant Context-Sensitive Half-Time of 3 to 4 minutes, regardless of whether it is infused for 15 minutes or 12 hours. It does not accumulate in tissues.
• Organ-Independent Clearance: Clearance is completely unaffected by severe hepatic failure, renal disease, or plasma pseudocholinesterase deficiencies (it is broken down by non-specific tissue and red blood cell esterases, not butyrylcholinesterase).
• Postoperative Pain Planning: Because remifentanil's analgesic effect dissipates completely within 5 to 10 minutes of stopping the infusion, the patient will awaken in severe pain unless longer-acting analgesics (e.g., hydromorphone, fentanyl, local anesthetic wound infiltration) are administered prior to discontinuation.
• Acute Opioid-Induced Hyperalgesia (OIH): High-dose remifentanil infusions (>0.2 to 0.3 mcg/kg/min) can trigger rapid acute tolerance and paradoxically increase postoperative pain sensitivity (hyperalgesia) via central NMDA receptor activation. Co-administration of subanesthetic ketamine may reduce this effect.

Hydromorphone (Dilaudid)

Hydromorphone is a semisynthetic phenanthrene derivative 5 to 7 times more potent than morphine. It has an onset of 2 to 5 minutes, peak effect at 10 to 20 minutes, and duration of 3 to 4 hours. It undergoes hepatic Phase II glucuronidation into hydromorphone-3-glucuronide (H3G), which has neurotoxic properties but lacks the potent respiratory depressant 6-glucuronide metabolite seen with morphine. It causes minimal histamine release and is widely used for moderate-to-severe postoperative surgical pain.

---

Perioperative Adverse Effects & Life-Threatening Complications

Dose-Dependent Respiratory Depression

All mu-opioid agonists directly depress medullary and pontine respiratory rhythm generators, producing two cardinal changes in respiratory physiology:

1. A rightward shift of the ventilatory response curve to arterial carbon dioxide (PaCO₂), increasing the apneic threshold.
2. A marked flattening of the slope of the CO₂ response curve, meaning that elevations in PaCO₂ fail to stimulate a compensatory increase in minute ventilation.

Opioid-induced hypoventilation is characterized by a profound reduction in respiratory rate (bradypnea) with relatively preserved or deep tidal volumes in awake patients; however, as sedation deepens, tidal volume falls, leading to progressive hypercapnia, respiratory acidosis, and hypoxic cardiac arrest.

Opioid-Induced Chest Wall Rigidity ("Wooden Chest Syndrome")

Chest wall rigidity is a severe, life-threatening complication characterized by sudden, intense hypertonus of the thoracoabdominal musculature, diaphragm, and vocal cords, rendering manual bag-valve-mask ventilation and tracheal intubation impossible.

+-----------------------------------------------------------------------------+
|             "WOODEN CHEST SYNDROME" (OPIOID CHEST RIGIDITY)                 |
| - ETIOLOGY: Rapid intravenous bolus administration of large doses of highly |
|   lipophilic synthetic opioids (Fentanyl, Remifentanil, Sufentanil,         |
|   Alfentanil).                                                              |
| - MECHANISM: Centrally mediated by mu receptors in the basal ganglia,       |
|   striatum, and substantia nigra, stimulating spinal motoneurons and        |
|   causing acute vocal cord adduction and chest wall splinting.              |
| - CLINICAL PRESENTATION:                                                    |
|   1. Instantaneous inability to ventilate: bag-valve-mask is completely     |
|      non-compliant. Peak airway pressures spike >50 cmH2O.                  |
|   2. Vocal cords are tightly adducted and rigid; glottic opening cannot     |
|      be visualized or traversed with an endotracheal tube.                  |
|   3. Rapid development of profound hypoxemia, hypercapnia, and arrest.      |
| - DEFINITIVE EMERGENCY MANAGEMENT:                                          |
|   1. Administer a NEUROMUSCULAR BLOCKING AGENT: Succinylcholine             |
|      (1.0 to 1.5 mg/kg IV) or Rocuronium (1.0 to 1.2 mg/kg IV) immediately  |
|      relaxes the skeletal muscle rigidity, allowing ventilation/intubation. |
|   2. Alternatively, administer NALOXONE (0.1 to 0.4 mg IV) to reverse the  |
|      opioid, though this will reverse all surgical analgesia.               |
+-----------------------------------------------------------------------------+

Sphincter of Oddi Spasm

Opioids induce dose-dependent contraction of the circular smooth muscle of the Sphincter of Oddi at the choledochoduodenal junction, raising intrabiliary pressure from a normal baseline of 10 mmHg up to 20 to 30 mmHg:

• Clinical Manifestation: During intraoperative cholangiography (e.g., cholecystectomy or common bile duct exploration), opioid-induced spasm prevents radiopaque contrast from entering the duodenum. This mimics a retained common bile duct gallstone and can lead to unnecessary surgical duct exploration.
• Treatment:
  1. Glucagon (1.0 to 2.0 mg IV): Directly relaxes biliary smooth muscle without reversing systemic opioid analgesia (first-line therapy).
  2. Nitroglycerin (100 to 200 mcg IV): Relaxes vascular and biliary smooth muscle.
  3. Naloxone (0.04 to 0.1 mg IV): Reverses the spasm, but also reverses systemic analgesia.
  4. Atropine (0.4 to 0.6 mg IV): Variable antimuscarinic relaxation.

Other Adverse Effects

• Cardiovascular: Bradycardia caused by direct stimulation of the central vagal motor nucleus in the medulla. Venodilation reduces preload, predisposing hypovolemic patients to hypotension.
• Gastrointestinal: Decreased propulsive peristalsis, delayed gastric emptying, and contraction of bowel sphincters leading to postoperative paralytic ileus and constipation.
• Nausea & Vomiting: Direct stimulation of the Chemoreceptor Trigger Zone (CTZ) in the area postrema of the fourth ventricle (dopamine and serotonin pathways), coupled with enhanced vestibular sensitivity.
• Pupillary Miosis: Stimulation of the parasympathetic autonomic component of the Edinger-Westphal nucleus of the oculomotor nerve (cranial nerve III), producing classic "pinpoint pupils."

---

Non-Opioid Analgesic: Ketorolac (Toradol)

The ASATT outline lists Toradol (ketorolac) as its example nonsteroidal anti-inflammatory drug (NSAID). Ketorolac is an injectable NSAID used in multimodal analgesia to reduce opioid requirements.

• Mechanism: Nonselective, reversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. It is analgesic, anti-inflammatory, and antipyretic, and because it has no opioid receptor activity it does not cause respiratory depression.
• Adult IV/IM dosing (U.S. label): Under 65 years, 30 mg every 6 hours (maximum 120 mg/day). For patients 65 or older, under 50 kg, or with moderately elevated serum creatinine, 15 mg every 6 hours (maximum 60 mg/day).
• Duration limit: A boxed warning limits combined IV, IM, and oral ketorolac therapy to 5 days.
• Time course: Analgesia begins in about 30 minutes, peaks in 1 to 2 hours, and lasts about 4 to 6 hours.

Label Contraindications to Know

• Active or recent gastrointestinal bleeding or peptic ulcer disease
• Advanced renal impairment, or risk of kidney failure from volume depletion
• Suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis, or high bleeding risk, including use as a prophylactic analgesic before major surgery
• Treatment of perioperative pain in coronary artery bypass graft (CABG) surgery
• Labor and delivery, and neuraxial (epidural or intrathecal) administration because of its alcohol content
• Prior allergic reactions to aspirin or other NSAIDs, and current use of aspirin, other NSAIDs, probenecid, or pentoxifylline

---

Opioid Reversal Protocols: Naloxone (Narcan)

Naloxone is a synthetic N-allyl derivative of morphinan that functions as a competitive pure antagonist at mu, kappa, and delta opioid receptors, with highest affinity for the Mu receptor.

NALOXONE PHARMACOKINETIC PROFILE:
- Mechanism: Pure competitive receptor antagonist
- Onset of Action: 1 to 2 minutes IV; 2 to 5 minutes IM/IN
- Duration of Clinical Action: roughly 30 to 60 MINUTES
- Elimination Half-Life: 60 to 90 minutes
- Primary Metabolism: Hepatic Phase II Glucuronidation to Naloxone-3-Glucuronide

Titration Protocols: Preserving Analgesia vs. Complete Reversal

• Emergency Resuscitation (Apnea / Cardiac Arrest): In complete respiratory arrest or severe acute overdose, administer 0.4 to 2.0 mg IV, IM, or IN immediately, repeated every 2 to 3 minutes until spontaneous breathing resumes.
• Postoperative Titration (Reversing Respiratory Depression while Preserving Analgesia): In the post-anesthesia care unit (PACU), sudden complete reversal of opioids precipitates excruciating pain and dangerous autonomic discharge. Naloxone should be carefully titrated:
  1. Dilute one 0.4 mg (400 mcg) ampule of naloxone into 9 mL of normal saline to yield a concentration of 40 mcg/mL (0.04 mg/mL).
  2. Administer 1 to 2 mL (40 to 80 mcg IV) every 2 to 3 minutes.
  3. Stop titration as soon as the patient's spontaneous respiratory rate exceeds 10 to 12 breaths/minute and adequate tidal volume returns, before full reversal of surgical antinociception occurs.

The Danger of Renarcotization

The most critical failure mode in opioid reversal is renarcotization:

• Mechanism: Naloxone has an effective clinical duration of action of only about 30 to 60 minutes. In contrast, most perioperative opioids have far longer clinical durations (morphine: 4–5 hours; hydromorphone: 3–4 hours; fentanyl: 1–2 hours). Furthermore, active metabolites (such as M6G) persist for many hours, especially in renal dysfunction.
• Clinical Consequence: As naloxone is metabolized and clears from the brain, circulating opioid agonist molecules re-bind to unoccupied mu receptors. A patient who was successfully revived and awake can lapse back into unresponsiveness, severe hypoventilation, and fatal respiratory arrest 45 to 60 minutes after the initial reversal dose.
• Clinical Protocol: Any patient receiving naloxone reversal must remain under continuous cardiopulmonary and pulse oximetry monitoring for at least 2 hours after the last naloxone dose. For long-acting opioids, set up a continuous naloxone infusion (typically calculated at two-thirds of the initial successful reversal bolus dose per hour).

Complications of Rapid High-Dose Reversal: The Sympathetic Crisis

Administering a rapid, high-dose, un-titrated intravenous push of naloxone (e.g., 0.4 to 1.0 mg IV push) abruptly unmasks severe pain and triggers an immediate, massive release of endogenous catecholamines (epinephrine and norepinephrine) from the sympathetic nervous system and adrenal medulla:

1. Severe Hypertension and Tachycardia: Blood pressure can surge dramatically, causing acute left ventricular strain, intracranial hemorrhage, or myocardial infarction.
2. Malignant Ventricular Dysrhythmias: Severe catecholamine surges precipitate premature ventricular contractions (PVCs), ventricular tachycardia (VT), and ventricular fibrillation (VF).
3. Flash Pulmonary Edema: The combination of massive systemic vasoconstriction (shifting blood from the peripheral into the pulmonary circulation) and acute left ventricular afterload mismatch causes pulmonary capillary pressures to surge, leading to life-threatening flash neurogenic/cardiogenic pulmonary edema.
4. Intractable Pain and Agitation: Abrupt awakening in agonizing surgical pain leads to combative delirium, surgical wound dehiscence, and severe patient distress.